
BioNTech's BNT113 cancer trial misses first endpoint but continues to assess overall survival.
BioNTech's experimental cancer treatment BNT113, combined with pembrolizumab, failed to show a significant improvement in progression-free survival in its Phase 2/3 AHEAD-MERIT trial. Despite missing this first primary endpoint, the trial will procee...





